ClavystBio is a life sciences venture investor set up by Temasek. 
Our mission is to accelerate the commercialization of life sciences breakthroughs into health impact. We invest and partner with innovators, entrepreneurs and founders to launch and grow global companies in Singapore. We foster partnerships among academics, industry and investors, and convene life sciences communities at our collaborative innovation space Node 1. Together, we advance Singapore as a global life sciences translational hub. 

Since our inception in 2022, ClavystBio has committed over US$220m to biotech, diagnostics and digital health companies, as well as early-stage VC funds. 


ClavystBio

Thank you to all our partners and friends, especially those who travelled long distances, for joining us at ClavystBio Connects 2023. We look forward to furthering the great connections and rich conversations that day!

For those who weren't able to join, here's a short video of the day's highlights. Enjoy! 

#collaboratetoinnovate #clavystbio #clavystbioconnects

In the latest episode of ClavystBio Conversations, 65LAB partners Thomas Hanke (Evotec), Christina K. Isacson Ph.D. (Lightstone Ventures), and Shuwen Koh (National University Health System) discuss what it takes to foster #venture creation and build global #biotech companies. 

65LAB is a unique company creation vehicle established by ClavystBio, Evotec, Leaps by Bayer, Lightstone Ventures, Polaris Partners, and the Polaris Innovation Fund to leverage breakthrough science from A*STAR - Agency for Science, Technology and Research, Duke-NUS Medical School and National University of Singapore for #humanhealth impact.

Learn more about 65LAB here: https://65lab.sg/
Watch episode here: https://lnkd.in/ggrN8Qv6


ClavystBio  Senior Associate Ning Mao  shared the stage with Rena Dharmawan  Kevin SW TAN  and Judy Sng  at NUS Yong Loo Lin School of Medicine’ Science Festival in a panel on career paths in #biomedical science.

Moderator Hataitip Tasena, PhD took a poll among the audience of grad students, post docs and undergrads: about 30% were set on pursuing academia, 40% were still on the fence, and 30% were interested in exploring alternative career options.

 At ClavystBio, we see the diverse backgrounds of our team as a strength when it comes to #venturebuilding. Some of us come from academia, others from finance, public sector, arts and the world of start-ups. As Ning, an academic transplant herself, shared: “Keep your options open, network widely and talk to others who have diverged from one path and found fulfilment in another in the biomedical field.”

Thanks to NUS and the excellent fellow panellists for widening perspectives and helping bridge the gap between academia and industry.

Thank you BioCentury Inc. for featuring Sunbird Bio and their novel use of exosomes to tackle #Alzheimers. 

Originating in Prof Huilin Shao's lab at National University of Singapore, Sunbird’s amplified plasmonic exosome (APEX) technology detects extracellular vesicles and the proteins bound to them —potentially revolutionizing early detection and response monitoring in clinical trials. 

“It can detect down to the nanometer size, but most importantly, it’s about 10,000 times more sensitive than currently available blood-based Alzheimer’s diagnostic tests,” said Sunbird Executive Chairman and CEO John McDonough   

Read more here: https://lnkd.in/g8fwatye

#venturebuilding #innovation #diagnostics 
ClavystBio   Polaris Partners  S32 

Thanks Lianhe Zaobao 联合早报 for featuring ClavystBio in this trend overview, highlighting the resilience of Singapore's VC scene amid the challenging macroeconomic climate. 

Industry leaders spoke about the growing interest in early-stage innovations in local companies here, with the most active venture capital deal activity in ASEAN. 

"Local innovation and clinical performance needs to be quickly transformed and commercialized" said ClavystBio CEO Khoo Shih, explaining ClavystBio's mission to provide catalytic capital across the ecosystem to translate outstanding science in Singapore into human health impact. 

Read more: https://lnkd.in/gG_u-Etf

#innovation #entrepreneurship #investments

Clario is a biotechnology company specializing in novel therapeutics development.

Clario

BeiGene is a biotechnology company focused on developing innovative molecularly targeted and immuno-oncology cancer therapeutics.

BeiGene

Revvity is a biotechnology company dedicated to the development of novel therapeutics for various diseases.

Revvity

Ginkgo Bioworks is a biotechnology company that designs custom microbes for customers across multiple markets.

Ginkgo Bioworks

PacBio is a biotechnology company specializing in the development of DNA sequencing systems.

PacBio

CareDx is a biotechnology company focused on improving organ transplant outcomes through innovative diagnostics.

CareDx

Sage Therapeutics is a biopharmaceutical company committed to developing novel medicines to treat life-altering central nervous system disorders.

Sage Therapeutics

IRBM Group is a research organization focused on drug discovery and development in the biotech and pharmaceutical industries.

IRBM Group

FibroGen is a biopharmaceutical company dedicated to creating first-in-class medicines for the treatment of chronic and life-threatening conditions.

FibroGen

Worldwide Clinical Trials is a global CRO providing full-service drug development services to the pharmaceutical and biotechnology industries.

Worldwide Clinical Trials

Cayman Chemical is a biochemical research company that supplies biochemical tools for life science research.

Cayman Chemical

BlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases.

BlueRock Therapeutics

Vesigen Therapeutics is a biotechnology company specializing in the development of novel therapeutics using extracellular vesicles.

Vesigen Therapeutics

NextGen Bio is a biotechnology company focused on developing novel therapeutics for various medical conditions.

NextGen Bio

Triana Biomedicines, Inc. is a biotechnology company dedicated to the development of innovative therapeutics for medical needs.

Triana Biomedicines, Inc.

Clavyst Bio is a biotechnology company that specializes in the development of novel therapeutics for the treatment of diseases with high unmet medical needs. The company leverages its proprietary drug discovery platform to identify and advance small molecule therapeutics.

news impact assignment basic	general
public peers	general	May 15, 2024 3:22 PM	bcf13d3e
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	b5996709
crunchbase profile	general
li profile	general	May 15, 2024 3:22 PM	9b6fa5f8
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CLAVYSTBIO

Clavyst Bio